• Galapagos and Gilead are in advanced discussions on a strategic collaboration related to Ouro Medicines assets, including OM336 (gamgertamig).
• Proposed terms include Galapagos paying 50% of the USD 1.68 billion upfront consideration and 50% of up to USD 500 million in contingent milestones.
• The parties would collaborate on development of OM336, with Galapagos covering costs through initiation of registrational studies.
• Gilead would hold worldwide commercialization rights outside Greater China and would pay Galapagos royalties of 20%-23% of net sales.
• An amended OLCA is contemplated to allow up to USD 500 million of cash to be used by Galapagos, including up to USD 150 million for potential share repurchases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galapagos NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603231825PRIMZONEFULLFEED1001171777) on March 23, 2026, and is solely responsible for the information contained therein.